MARKET

ACRS

ACRS

Aclaris Therapeutics Inc
NASDAQ
15.18
-0.74
-4.65%
After Hours: 15.18 0 0.00% 16:17 12/07 EST
OPEN
15.93
PREV CLOSE
15.92
HIGH
16.38
LOW
15.13
VOLUME
251.35K
TURNOVER
0
52 WEEK HIGH
18.96
52 WEEK LOW
9.26
MARKET CAP
1.01B
P/E (TTM)
-11.7821
1D
5D
1M
3M
1Y
5Y
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Benzinga · 6d ago
Goldman Sachs Initiates Aclaris Therapeutics at Buy With $25 Price Target
Goldman Sachs Initiates Aclaris Therapeutics at Buy With $25 Price Target
MT Newswires · 6d ago
BRIEF-Aclaris Therapeutics & Pediatrix Therapeutics Announce License Agreement For Ati-1777 In China
Reuters · 11/29 12:28
Aclaris Therapeutics And Pediatrix Therapeutics Announce License Agreement For ATI-1777 In Greater China; Aclaris To Receive $5M Upfront Payment And Up To $91M In Milestones
Benzinga · 11/29 12:04
Aclaris Therapeutics Announces Key Leadership Transitions; Douglas Manion, M.D. Appointed To Succeed Dr. Walker As CEO And Appointed To The Board Of Directors; Kevin Balthaser Appointed CFO To Succeed Retiring Frank Ruffo
Benzinga · 11/22 21:03
Aclaris Therapeutics Announces Key Leadership Transitions
- Dr. Neal Walker to transition to Chair of the Board of Directors - Current Board Chair Christopher Molineaux to become Lead Independent Director - Douglas Manion, M.D. appointed to succeed Dr. Walker as Chief Executive Officer and appointed to the Board ...
GlobeNewswire · 11/22 21:01
Aclaris Therapeutics Names New Leadership Team With Christopher Molineaux as Chief Executive Officer
Aclaris Therapeutics Names New Leadership Team With Christopher Molineaux as Chief Executive Officer
MT Newswires · 11/22 17:35
Aclaris Therapeutics Looks Promising on the Charts
Aclaris Therapeutics is a biotech play that is focused on "leveraging core expertise in drug discovery and development and kinase inhibition to develop novel, small molecule therapies to help people impacted by under served immuno-inflammatory conditions....
TheStreet.com · 11/16 17:10
More
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing drug candidates for immuno-inflammatory diseases. The Company is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. The Company’s drug candidates are Zunsemetinib (ATI-450), ATI-1777 and ATI-2138. The Company’s ATI-450, an investigational oral, small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK 1/3 inhibitor compound, for the treatment of atopic dermatitis. The Company is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for T-cell mediated autoimmune diseases. It is also developing oral gut biased JAK inhibitors, as a potential treatment for inflammatory bowel disease.

Webull offers kinds of Aclaris Therapeutics Inc stock information, including NASDAQ:ACRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACRS stock methods without spending real money on the virtual paper trading platform.